— Know what they know.
Not Investment Advice

ACAD NASDAQ

Acadia Pharmaceuticals Inc.
1W: -0.3% 1M: -4.5% 3M: -24.1% YTD: -24.9% 1Y: -9.2% 3Y: -13.9% 5Y: +12.2%
$20.17
+0.43 (+2.18%)
After Hours: $20.23 (+0.05, +0.27%)
Weekly Expected Move ±4.8%
$18 $19 $20 $21 $22
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 42 · $3.5B mcap · 170M float · 1.08% daily turnover · Short 54% of daily vol
Credit Risk of going bust: lower than 86% of companies Debt: 2.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.8%), Acadia Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $73.9M against a stock market value of $3.40B.
Distance to default 11.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.9M (short-term plus half of long-term), stock volatility 39.1%; Altman Z'' 3.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$1.6B +31.7% ▲
5Y CAGR: +14.9%
Total Liabilities
$337M -26.0% ▼
5Y CAGR: +16.7%
Shareholders Equity
$1.2B +67.5% ▲
5Y CAGR: +14.4%
Cash & Investments
$820M +8.4% ▲
5Y CAGR: +5.3%
Total Debt
$52M +0.4% ▲
5Y CAGR: +1.0%
Net Debt
-$126M +53.1% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$147M$115M$189M$320M$178M
Short-Term Investments$373M$302M$250M$436M$642M
Cash & ST Investments$521M$417M$439M$756M$820M
Net Receivables$65M$63M$102M$105M$148M
Inventory$8M$7M$36M$22M$35M
Other Current Assets$0$0$0$0$0
Total Current Assets$618M$508M$616M$938M$1.1B
Property, Plant & Equip.$66M$62M$56M$51M$55M
Goodwill & Intangibles$0$0$65M$120M$109M
Long-Term Investments$0$13M$6M$0$8M
Other Non-Current Assets$16M$5M$5M$79M$81M
Total Non-Current Assets$82M$80M$133M$249M$502M
Total Assets$700M$588M$749M$1.2B$1.6B
— Liabilities —
Accounts Payable$7M$13M$18M$16M$11M
Short-Term Debt$0$0$9M$0$12M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$26M$50M$92M$37M$255M
Total Current Liabilities$96M$126M$254M$395M$277M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$7M$9M$15M$18M$19M
Total Non-Current Liabilities$63M$62M$63M$60M$60M
Total Liabilities$159M$187M$317M$455M$337M
— Equity —
Common Stock$16K$16K$16K$16K$16K
Retained Earnings-$2.2B-$2.4B-$2.4B-$2.2B-$1.8B
Accumulated OCI-$192K-$975K$24K$292K$1M
Total Stockholders Equity$541M$400M$432M$733M$1.2B
Total Liabilities & Equity$700M$588M$749M$1.2B$1.6B
— Key Metrics —
Total Debt$64M$62M$57M$52M$52M
Net Debt-$83M-$53M-$131M-$268M-$126M
Total Investments$373M$315M$256M$436M$650M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms